Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 6Endometrial Neoplasms 6Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Prostatic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Melanoma 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent Uterine Sarcoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1Specimen Handling 1Sirolimus 1Oxaliplatin 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Floxuridine 1Fentanyl 1Disulfides 1CTLA-4 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Sirolimus × Gynecologic × Clear all
NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
252 enrolled 20 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡